TH-3424
TH-3424 Basic information
- Product Name:
- TH-3424
- Synonyms:
-
- OBI-3424
- TH-3424
- Phosphinic acid, P,P-bis(1-aziridinyl)-, (1R)-1-[3-[3-[(dimethylamino)carbonyl]phenoxy]-4-nitrophenyl]ethyl ester
- CAS:
- 2097713-68-1
- MF:
- C21H25N4O6P
- MW:
- 460.42
- Mol File:
- 2097713-68-1.mol
More
Less
TH-3424 Chemical Properties
- Boiling point:
- 611.3±65.0 °C(Predicted)
- Density
- 1.42±0.1 g/cm3(Predicted)
- storage temp.
- -20°C, protect from light
- solubility
- DMSO : 50 mg/mL (108.60 mM; Need ultrasonic)
- pka
- 0.19±0.20(Predicted)
- form
- -20°C Solid,>-20°C Oil
More
Less
TH-3424 Usage And Synthesis
Uses
OBI-3424 (TH-3424) is a proagent that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. OBI-3424 can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research[1].
in vivo
OBI-3424 (0.5-2.5 mg/kg; i.p.; once weekly; for 3 weeks) treatment induces regressions in PDXs mice and results in prolongation of mouse event-free survival[1].
| Animal Model: | Female NSG mice (20-25 g) bearing patient-derived xenografts (PDX)[1] |
| Dosage: | 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg |
| Administration: | Intraperitoneal injection; once weekly; for 3 weeks |
| Result: | Resulted in prolongation of mouse event-free survival. |
References
[1] Kathryn Evans, et al. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clin Cancer Res. 2019 Jul 15;25(14):4493-4503. DOI:10.1158/1078-0432.CCR-19-0551
TH-3424Supplier
ShangHai Caerulum Pharma Discovery Co., Ltd.
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
Kaixin Chemical (Hong Kong) Limited
- Tel
- 010-88886666-01 13112345678
- loyson@tcypharm.com
TargetMol Chemicals Inc.
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd
- Tel
- 15317229551
- 15151849396@163.com
TargetMol Chemicals Inc.
- Tel
- 4008200310
- marketing@tsbiochem.com